72 results on '"Basse C"'
Search Results
2. Carcinome bronchique non à petites cellules : nouvelles addictions oncogéniques, diagnostic et perspectives
- Author
-
Basse, C., Swalduz, A., Mc Leer, A., Moro-Sibilot, D., Remon, J., and Girard, N.
- Published
- 2021
- Full Text
- View/download PDF
3. Thoracic and abdominal aortic dissection in a hypertensive hyperthyroid cat
- Author
-
Veciana Basse, C, primary and Testault, I, additional
- Published
- 2024
- Full Text
- View/download PDF
4. 1390P Clinical characteristics and treatment outcomes of patients with thoracic SMARCA4-deficient tumour
- Author
-
Duparc, I., Castanet, E., Basse, C., Fallet, V., Baldacci, S., Demontrond, P., Oulkhouir, Y., Cousin, S., Arpin, D., Fournel, P., Leite Ferreira, D., Piton, N., and Guisier, F.
- Published
- 2024
- Full Text
- View/download PDF
5. 54P Overall survival in patients with metastatic lung cancer from 2000 to 2020: Implementation of innovative strategies in a real-world setting
- Author
-
Basse, C., primary, Carton, M., additional, Milder, M., additional, Beaucaire Danel, S., additional, Daniel, C., additional, Du Rusquec, P., additional, Livartowski, A., additional, and Girard, N., additional
- Published
- 2022
- Full Text
- View/download PDF
6. 37P Sotorasib-induced liver and non-liver toxicity associated with sequential sotorasib following anti-PD(L)1 in KRASG12C mutant lung cancer
- Author
-
Chour, A., primary, Denis, J., additional, Lafitte, C., additional, Mascaux, C., additional, Zysman, M., additional, Lemaitre, A., additional, Swalduz, A., additional, Gounant, V., additional, Cortot, A., additional, Darrason, M., additional, Cadranel, J., additional, Auclin, E., additional, Basse, C., additional, Tissot, C., additional, Decroisette, C., additional, Bombaron, P., additional, Giroux-Leprieur, E., additional, Falchero, L., additional, Lebossé, F., additional, and Duruisseaux, M., additional
- Published
- 2022
- Full Text
- View/download PDF
7. Cancer bronchique après un cancer du sein : effets de la radiothérapie mammaire et du tabagisme
- Author
-
Ancel, J., primary, Basse, C., additional, Beaucaire-Danel, S., additional, Massiani, M.A., additional, Du Rusquec, P., additional, Daniel, C., additional, Beddok, A., additional, and Girard, N., additional
- Published
- 2022
- Full Text
- View/download PDF
8. RADIORYTHMIC: Phase III, Opened, Randomized Study of Postoperative Radiotherapy Versus Surveillance in Stage IIb/III of Masaoka Koga Thymoma after Complete Surgical Resection
- Author
-
Basse, C., Botticella, A., Molina, T.J., Falcoz, P.E., Oulkhouir, Y., Kerjouan, M., Pichon, E., Westeel, V., Thiberville, L., Quantin, X., Clément-Duchêne, C., Khalifa, J., Tinier, F. Le, Ginoux, M., Thillays, F., Mordant, P., Besse, B., Thomas, P.A., Péchoux, C. Le, and Girard, Nicolas
- Published
- 2021
- Full Text
- View/download PDF
9. 1742TiP RADIORYTHMIC: Phase III, opened, randomized study of post-operative radiotherapy (PORT) versus surveillance in stage IIb/III of Masaoka Koga thymoma after complete surgical resection
- Author
-
Basse, C., primary, Botticella, A., additional, Molina, T., additional, Falcoz, P-E., additional, Oulkhouir, Y., additional, Kerjouan, M., additional, Pichon, E., additional, Calcagno, F., additional, Thiberville, L., additional, Quantin, X., additional, Clément-Duchêne, C., additional, Khalifa, J., additional, Mazieres, J., additional, Le Tinier, F., additional, Dansin, E., additional, Thillays, F., additional, Besse, B., additional, Thomas, P-A., additional, Le Pechoux, C., additional, and Girard, N., additional
- Published
- 2021
- Full Text
- View/download PDF
10. Efficacité et tolérance de l’association ténofovir-lamivudine-éfavirenz chez les patients VIH-1 à la clinique des maladies infectieuses du CHNU de Fann à Dakar
- Author
-
Diop, S. A., Fortes-Déguénonvo, L., Seydi, M., Dieng, A. B., Basse, C. D., Manga, N. M., Dia, N. M., Ndaw, G., Ndour, C. T., Soumaré, M., Diop, B. M., and Sow, P. S.
- Published
- 2013
- Full Text
- View/download PDF
11. Efficacy and tolerance of tenofovir-lamivudine-efavirenz combination therapy in HIV 1 patients in a resource limited setting: P207
- Author
-
Ndow, G, Diop, S A, Seydi, M, Fortes-Déguénonvo, L, Manga, N M, Dia, N M, Basse, C D, Ndour, C T, Soumare, M, Diop, B M, and Sow, P S
- Published
- 2012
12. Efficacité et tolérance de l’association ténofovir-lamivudine-éfavirenz chez les patients VIH-1 à la clinique des maladies infectieuses du CHNU de Fann à Dakar
- Author
-
Diop, S. A., primary, Fortes-Déguénonvo, L., additional, Seydi, M., additional, Dieng, A. B., additional, Basse, C. D., additional, Manga, N. M., additional, Dia, N. M., additional, Ndaw, G., additional, Ndour, C. T., additional, Soumaré, M., additional, Diop, B. M., additional, and Sow, P. S., additional
- Published
- 2012
- Full Text
- View/download PDF
13. Genetic mapping of a susceptibility locus for insulin-dependent diabetes mellitus on chromosome llq
- Author
-
Hashimoto, L., primary, Habita, C., additional, Beressi, J. P., additional, Delepine, M., additional, Basse, C., additional, Cambon-Thomsen, A., additional, Deschamps, I., additional, Rotter, J. I., additional, Djoulah, S., additional, James, M. R., additional, Froguel, P., additional, Weissenbach, J., additional, Lathrop, G. M., additional, and Julier, C., additional
- Published
- 1994
- Full Text
- View/download PDF
14. Intrachromosomal recombination in plants.
- Author
-
Peterhans, A., primary, Schlüpmann, H., additional, Basse, C., additional, and Paszkowski, J., additional
- Published
- 1990
- Full Text
- View/download PDF
15. The use of cognitive bias as an indicator of affective state in the domestic dog
- Author
-
Rachel Casey, Ja, Brooks, Basse, C., Ohp, Burman, and Michael Mendl
16. Real-World Survival Impact of New Treatment Strategies for Lung Cancer: A 2000-2020 French Cohort.
- Author
-
Basse C, Carton M, Milder M, Geiss R, Du Rusquec P, Daniel C, Massiani MA, Livartowski A, and Girard N
- Abstract
Over the past 20 years, several innovative therapies have been implemented in the treatment of lung cancer that have had reported survival benefits in clinical trials. Whether these improvements translate into the clinic setting has not been studied yet. We retrospectively analyzed all patients consecutively treated at Institute Curie for metastatic lung cancer. Diagnosis date was used to define three periods, based on the approvals of novel treatment strategies in the first-line setting, including targeted therapies in 2010 and immunotherapy in 2018. Endpoints included Overall survival (OS), survival rate of 2 years and 5 years, and a conditional survival rate of 2 years (if still alive at 6 months from treatment initiation). A total of 673 patients were identified for Period 1-2000 to 2009, 752 for Period 2-2010 to 2017, and 768 for Period 3-2018 to 2020. Median OS in the whole cohort was 11.1, 15.5, and 16.2 months, respectively. Median OS for patients with NSCLC or SCLC was 11.2, 17.2, and 18.2 months, or 10.9, 11.7, and 11.2 months, respectively. The two-year conditional survival was more favorable for NSCLC than SCLC patients. Outcomes were statistically higher for women as compared to men in all periods and all subgroups. Survival of patients with metastatic lung cancer has improved over the past 20 years, mostly in NSCLC, along with the implementation of novel treatment strategies.
- Published
- 2024
- Full Text
- View/download PDF
17. Recommendations for Post-Operative RadioTherapy After Complete Resection of Thymoma-a French DELPHI Consensus Initiative.
- Author
-
Basse C, Khalifa J, Thillays F, Le Pechoux C, Maury JM, Bonte PE, Coutte A, Pourel N, Bourbonne V, Pradier O, Belliere A, Le Tinier F, Deberne M, Tanguy R, Denis F, Padovani L, Zaccariotto A, Molina T, Chalabreysse L, Brioude G, Delatour B, Faivre JC, Cao K, Giraud P, Riet FG, Thureau S, Antoni D, Massabeau C, Keller A, Bonnet E, Lerouge D, Martin E, Girard N, and Botticella A
- Subjects
- Humans, France, Postoperative Care methods, Postoperative Care standards, Thymoma radiotherapy, Thymoma surgery, Thymoma pathology, Thymus Neoplasms radiotherapy, Thymus Neoplasms surgery, Thymus Neoplasms pathology, Delphi Technique, Consensus
- Abstract
Introduction: Thymomas are rare intrathoracic malignancies that can relapse after surgery. Whether or not Post-Operative RadioTherapy (PORT) should be delivered after surgery remains a major issue. RADIORYTHMIC is an ongoing, multicenter, randomized phase 3 trial addressing this question in patients with completely R0 resected Masaoka-Koga stage IIb/III thymoma. Experts in the field met to develop recommendations for PORT., Methods: A scientific committee from the RYTHMIC network identified key issues regarding the modalities of PORT in completely resected thymoma. A DELPHI method was used to question 24 national experts, with 115 questions regarding the following: (1) imaging techniques, (2) clinical target volume (CTV) and margins, (3) dose constraints to organs at risk, (4) dose and fractionation, and (5) follow-up and records. Consensus was defined when opinions reached more than or equal to 80% agreement., Results: We established the following recommendations: preoperative contrast-enhanced computed tomography (CT) scan is recommended (94% agreement); optimization of radiation delivery includes either a four-dimensional CT-based planning (82% agreement), a breath-holding inspiration breath-hold-based planning, or daily control CT imaging (81% agreement); imaging fusion based on cardiovascular structures of preoperative and planning CT scan is recommended (82% agreement); right coronary and left anterior descending coronary arteries should be delineated as cardiac substructures (88% agreement); rotational RCMI/volumetric modulated arc therapy is recommended (88% agreement); total dose is 50 Gy (81% agreement) with 1.8 to 2 Gy per fraction (94% agreement); cardiac evaluation and follow-up for patients with history of cardiovascular disease are recommended (88% agreement) with electrocardiogram and evaluation of left ventricular ejection fraction at 5 years and 10 years., Conclusion: This is the first consensus for PORT in thymoma. Implementation will help to harmonize practices., Competing Interests: Disclosure The authors have no conflict of interest to disclose concerning the current work., (Copyright © 2024 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
18. Management of sotorasib-related adverse events and hepatotoxicities following anti-PD-(L)1 therapy: Experience with sotorasib in two French anti-cancer centers and practical guidance proposal.
- Author
-
Chour A, Basse C, Lebossé F, Bonte PE, Girard N, and Duruisseaux M
- Subjects
- Humans, Male, Female, Aged, Middle Aged, France, Immune Checkpoint Inhibitors adverse effects, Immune Checkpoint Inhibitors therapeutic use, Aged, 80 and over, Pyridines therapeutic use, Pyridines adverse effects, Retrospective Studies, Adult, Pyrimidines therapeutic use, Pyrimidines adverse effects, Drug-Related Side Effects and Adverse Reactions etiology, Diarrhea chemically induced, B7-H1 Antigen antagonists & inhibitors, Disease Management, Practice Guidelines as Topic, Chemical and Drug Induced Liver Injury etiology, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Piperazines
- Abstract
Introduction: Sotorasib is a first-in-class KRASG12C inhibitor that showed significant clinical activity in KRAS
G12C -mutated non-small cell lung cancer (NSCLC). The most frequent grade 3 or 4 sotorasib-related adverse events (AEs) were diarrhea (4-12 %) and hepatotoxicity (10.1-15.1 %). Data is lacking about the management of these AEs, especially in patients receiving sequential anti-PD-(L)1 and sotorasib therapy. Our aim was to report the management of grade ≥ 2 sotorasib-related AEs in real-world setting and to propose practical guidance for the management of grade ≥ 2 sotorasib-related AEs and more generally KRASG12C inhibitors-related AEs., Materials and Methods: Records from all consecutive patients who initiated sotorasib through expanded access program in two French anti-cancer centers from January 1st 2021 to April 1st 2023 were reviewed to identify and grade sotorasib-related AEs, according to NCI-CTCAE v5.0., and to collect AEs management data. Patients were included in the analysis if they presented a grade ≥ 2 sotorasib-related AE., Results: From 57 patients identified, 21 met inclusion criteria including eighteen (86 %) who received sequential anti-PD-(L)1 and sotorasib therapy. Hepatotoxicity (76 %) and diarrhea (24 %) were the most common grade ≥ 2 sotorasib-related AEs. Among the 16 patients with a grade ≥ 2 hepatotoxicity, 12 (75 %) definitely discontinued sotorasib, among which 9 (56 %) after dose reductions and rechallenge, and five (32 %) received corticosteroids, allowing only one patient to resume sotorasib. Diarrhea and nausea were usually manageable and not associated with sotorasib discontinuation. We propose a step-by-step management practical guidance for sotorasib-related hepatotoxicity based on dose-reduction and careful monitoring. Liver biopsy is strongly encouraged for grade 3 and 4 hepatotoxicity to assess candidates for corticosteroids., Discussion: The experience with sotorasib might help better prevent, screen and manage sotorasib-related and other KRASG12C inhibitors-related AEs, particularly hepatotoxicity., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Ali Chour (ali.chour@chu-lyon.fr) reported no disclosures. Clémence Basse (clemence.basse@curie.fr) reported no disclosures. Nicolas Girard (nicolas.girard2@curie.fr) reported research grants/support from AstraZeneca, Amgen, Boehringer Ingelheim, Eli Lilly, Hoffmann-La Roche, Janssen, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Sivan, and Trizell; consultative services for Bristol Myers Squibb, AstraZeneca, AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly, Hoffmann-La Roche, Janssen, Merck, Merck Sharp & Dohme, Mirati, Novartis, Pfizer, Roche, Sanofi, and Sivan; payment for expert testimony from AstraZeneca; participation on a data safety monitoring board for Roche; leadership role in the International Thymic Malignancy Interest Group; and having employment of a family member with AstraZeneca. Fanny Lebossé (fanny.lebosse@chu-lyon.fr) reported no disclosures. Pierre-Emmanuel Bonté (pierreemmanuel.bonte@curie.fr) reported no disclosures. Michael Duruisseaux (michael.duruisseaux@chu-lyon.fr) reported Membership of an advisory council or committee for BMS, GSK, Sanofi, MSD, AstraZeneca, Abbvie, Takeda, Boehringer Ingelheim, Merus, Amgen, Guardant, Pfizer; consulting fees from Roche, BMS, MSD, AstraZeneca, AbbVie, Takeda, Boehringer Ingelheim, Gamamabs Pharma, Pfizer; research grants from Takeda, NanoString, Lilly, Blueprint.]., (Copyright © 2024. Published by Elsevier B.V.)- Published
- 2024
- Full Text
- View/download PDF
19. Second-trimester medical abortion after exposure to lorlatinib during early pregnancy, a case report.
- Author
-
Mawet M, Basse C, Barrois M, Gligorov J, Cadranel J, Chabbert-Buffet N, and Selleret L
- Subjects
- Female, Humans, Pregnancy, Adult, Protein-Tyrosine Kinases genetics, Protein-Tyrosine Kinases therapeutic use, Pregnancy Trimester, Second, Anaplastic Lymphoma Kinase genetics, Anaplastic Lymphoma Kinase therapeutic use, Proto-Oncogene Proteins genetics, Lactams, Macrocyclic pharmacology, Lactams, Macrocyclic therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms drug therapy, Lung Neoplasms genetics
- Abstract
Use of Lorlatinib, a third-generation tyrosine kinase inhibitor currently indicated in the treatment of non-small-cell lung cancer (NSCLC) with ALK or ROS1 gene fusion, is formally contra-indicated during pregnancy due to teratogenic effects observed during pre-clinical studies. We report the case of a 38-year-old woman with a ROS1-positive NSCLC, successfully treated with lorlatinib as second line therapy, who became pregnant while on treatment. Due to significant disease progression 12 weeks after lorlatinib stop and the great uncertainty on the pregnancy outcome, she finally decided to interrupt the pregnancy at 22 weeks of gestation. Echography and gross infant examination did not reveal any malformation. Pregnancies occurring under this kind of new oncologic treatment is expected to happen more frequently in the future. It seems therefore important to us to report any information on the topic to increase our level of knowledge and improve decision-making., Competing Interests: Declaration of Competing Interest The authors declare no conflict of interest., (Copyright © 2023 Elsevier Masson SAS. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
20. Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti-Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRAS G12C -Mutant Lung Cancer.
- Author
-
Chour A, Denis J, Mascaux C, Zysman M, Bigay-Game L, Swalduz A, Gounant V, Cortot A, Darrason M, Fallet V, Auclin E, Basse C, Tissot C, Decroisette C, Bombaron P, Giroux-Leprieur E, Odier L, Brosseau S, Creusot Q, Gueçamburu M, Meersseman C, Rochand A, Costantini A, Gaillard CM, Wasielewski E, Girard N, Cadranel J, Lafitte C, Lebossé F, and Duruisseaux M
- Subjects
- Humans, Proto-Oncogene Proteins p21(ras) therapeutic use, Retrospective Studies, Ligands, Cell Death, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms chemically induced, Antineoplastic Agents, Immunological therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung chemically induced, Drug-Related Side Effects and Adverse Reactions, Chemical and Drug Induced Liver Injury etiology
- Abstract
Introduction: Sequential anti-programmed cell death protein 1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) followed by small targeted therapy use is associated with increased prevalence of adverse events (AEs) in NSCLC. KRASG12C inhibitor sotorasib may trigger severe immune-mediated hepatotoxicity when used in sequence or in combination with anti-PD-(L)1. This study was designed to address whether sequential anti-PD-(L)1 and sotorasib therapy increases the risk of hepatotoxicity and other AEs., Methods: This is a multicenter, retrospective study of consecutive advanced KRAS
G12C -mutant NSCLC treated with sotorasib outside clinical trials in 16 French medical centers. Patient records were reviewed to identify sotorasib-related AEs (National Cancer Institute Common Classification Criteria for Adverse Events-Version 5.0). Grade 3 and higher AE was considered as severe. Sequence group was defined as patients who received an anti-PD-(L)1 as last line of treatment before sotorasib initiation and control group as patients who did not receive an anti-PD-(L)1 as last line of treatment before sotorasib initiation., Results: We identified 102 patients who received sotorasib, including 48 (47%) in the sequence group and 54 (53%) in the control group. Patients in the control group received an anti-PD-(L)1 followed by at least one treatment regimen before sotorasib in 87% of the cases or did not receive an anti-PD-(L)1 at any time before sotorasib in 13% of the cases. Severe sotorasib-related AEs were significantly more frequent in the sequence group compared with those in the control group (50% versus 13%, p < 0.001). Severe sotorasib-related AEs occurred in 24 patients (24 of 48, 50%) in the sequence group, and among them 16 (67%) experienced a severe sotorasib-related hepatotoxicity. Severe sotorasib-related hepatotoxicity was threefold more frequent in the sequence group compared with that in the control group (33% versus 11%, p = 0.006). No fatal sotorasib-related hepatotoxicity was reported. Non-liver severe sotorasib-related AEs were significantly more frequent in the sequence group (27% versus 4%, p < 0.001). Severe sotorasib-related AEs typically occurred in patients who received last anti-PD-(L)1 infusion within 30 days before sotorasib initiation., Conclusions: Sequential anti-PD-(L)1 and sotorasib therapy are associated with a significantly increased risk of severe sotorasib-related hepatotoxicity and severe non-liver AEs. We suggest avoiding starting sotorasib within 30 days from the last anti-PD-(L)1 infusion., (Copyright © 2023 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
21. [Capmatinib in advanced NSCLC for previously treated patients with MET exon 14 skipping mutation].
- Author
-
Basse C and Régaldo-Saint Blancard L
- Subjects
- Humans, Mutation, Exons, Proto-Oncogene Proteins c-met genetics, Protein Kinase Inhibitors therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Lung Neoplasms drug therapy, Lung Neoplasms genetics
- Published
- 2023
- Full Text
- View/download PDF
22. Accelerated subsequent lung cancer after post-operative radiotherapy for breast cancer.
- Author
-
Basse C, Ancel J, Massiani MA, Bonté PE, Beaulaton C, Beaucaire-Danel S, Milder M, Cao K, Daniel C, Du Rusquec P, Sablin MP, Kirova Y, Sage E, Beddok A, and Girard N
- Subjects
- Humans, Middle Aged, Female, Retrospective Studies, Lung pathology, Radiotherapy adverse effects, Breast Neoplasms radiotherapy, Breast Neoplasms pathology, Breast Neoplasms surgery, Lung Neoplasms etiology, Lung Neoplasms radiotherapy, Lung Neoplasms epidemiology, Adenocarcinoma surgery
- Abstract
Background: Post-operative whole breast radiotherapy for breast cancer (BC) may increase the risk of subsequent lung cancer (LC). The impact of radiotherapy intensification (boost) has not been specifically explored in this context. We investigated the role of radiation modalities on the development of subsequent LC among our patients treated by radiotherapy for localized BC., Methods: All patients with a diagnosis of LC between 2000 and 2020 with a history of prior localized BC treated by surgery and post-operative radiotherapy were retrospectively reviewed. Primary endpoint was time to first diagnosis of LC after BC treatment with radiotherapy (RT)., Results: From 98 patients who developed subsequent LC after primary BC treated with post-operative RT, 38% of patients (n = 37) received an additional RT boost, and 46% (n = 45) received hormonal treatment post radiation. A total of 61% (n = 60) were smokers. With regards to LC characteristics, adenocarcinoma was the most frequent histology (68%, n = 66); 36% (n = 35) harbored at least 1 molecular alteration, 57% (n = 20) of them being amenable to targeted therapy. Median time to first diagnosis of LC was 6 years [1.7-28.4 yrs] in the whole cohort. In the subgroup of patients treated with boost this time was reduced to 4 years [1.8-20.8 years] compared to 8 years for patients without boost [1.7-28.4 yrs] (p = 0.007). Boost, smoking usage, endocrine therapy, and age <50 yrs old at BC radiation remained independent factors associated with shorter time to first diagnosis of LC after BC treatment., Discussion: We report for the first time the potential impact of boost -part of BC radiation treatment- for BC on the risk of subsequent LC. The impact of low dose radiation on lung parenchyma could explain this phenomenon, but the underlying physiopathology is still under investigation. This work highlights the need for clinicians to identify patients at risk of developing faster subsequent thoracic malignancy after BC radiation, for implementing personalized surveillance., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
23. Gain of Aggressive Histological and Molecular Patterns after Acquired Resistance to Novel Anti-EGFR Therapies in Non-Small Cell Lung Cancer.
- Author
-
Basse C, Trabelsi-Grati O, Masliah J, Callens C, Kamal M, Freneaux P, Klijanienko J, Bieche I, and Girard N
- Subjects
- Humans, Disease Progression, Ki-67 Antigen genetics, Mutation, Protein Kinase Inhibitors pharmacology, Adenocarcinoma of Lung drug therapy, Adenocarcinoma of Lung genetics, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Drug Resistance, Neoplasm genetics, ErbB Receptors antagonists & inhibitors, ErbB Receptors genetics, Lung Neoplasms drug therapy, Lung Neoplasms genetics
- Abstract
Novel anti-EGFR therapies target resistance to standard-of-care anti-EGFR in patients with metastatic lung cancer. We describe tumors at progression versus at the initiation of novel anti-EGFR agents in patients with metastatic lung adenocarcinoma harboring EGFR mutation. This clinical case series reports the histological and genomic features and their evolution following disease progression under amivantamab or patritumab-deruxtecan in clinical trials. All patients had a biopsy at disease progression. Four patients harboring EGFR gene mutations were included. Three of them received anterior anti-EGFR treatment. Median delay to disease progression was 15 months (range: 4-24). At progression, all tumors presented a mutation in the TP53 signaling pathway associated with a loss of heterozygosis (LOH) of the allele in 75% ( n = 3), and two tumors (50%) presented an RB1 mutation associated with LOH. Ki67 expression increased above 50% (range 50-90%) in all samples compared to baseline (range 10-30%), and one tumor expressed a positive neuroendocrine marker at progression. Our work reports the potential molecular mechanisms of resistance under novel anti-EGFR in patients with metastatic EGFR-mutated lung adenocarcinoma, with the transformation to a more aggressive histology with acquired TP53 mutation and/or the increase in Ki67 expression. These characteristics are usually found in aggressive Small Cell Lung Cancer.
- Published
- 2023
- Full Text
- View/download PDF
24. Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers.
- Author
-
Girard N, Basse C, Schrock A, Ramkissoon S, Killian K, and Ross JS
- Subjects
- Humans, Mutation, Genomics, Phosphatidylinositol 3-Kinases genetics, Biomarkers, Biomarkers, Tumor genetics, Thymoma genetics, Thymus Neoplasms genetics, Neoplasms, Glandular and Epithelial genetics
- Abstract
Background: Thymic malignancies represent a heterogeneous group of rare thoracic cancers, which are classified according to the World Health Organization histopathologic classification, that distinguishes thymomas from thymic carcinomas. Data regarding the biology of those tumors are limited in the literature, and the vast majority have been obtained using surgical specimens from early-stage disease. Meanwhile, treatment of advanced, refractory thymic tumors currently relies on chemotherapy, with limited efficacy. Comprehensive genomic profiling (CGP) of advanced, refractory tumors would open some opportunities for innovative treatments., Patients and Methods: A total of 90 and 174 consecutive patients with thymoma or thymic carcinoma, respectively, for whom formalin-fixed, paraffin-embedded specimens from recurrent, refractory tumor were sequenced, were included. Sequencing was performed using hybridization-captured, adaptor ligation-based libraries to a mean coverage depth of >500× for up to 315 cancer-related genes plus 37 introns from 28 genes frequently rearranged in cancer., Results: Thymomas featured a low frequency of genomic alterations (average of 1.8/tumor), and low levels of TMB. The genomic alterations identified in more than 10% of cases were in the CDKN2A/B and TP53 genes. Amplification in the NTRK1 gene was found in an unresectable, stage III, type B3 thymoma. Thymic carcinomas featured a significantly higher frequency of alterations at 4.0/tumor (P < .0001). Clinically relevant genomic alterations were observed in the CDKN2A, KIT, and PTEN/PI3K/MTOR pathways. Elevated TMB in thymic carcinomas was uncommon with only 6% of cases featuring ≥10 mutations/Mb., Conclusions: Our cohort is the largest available so far, reporting on CGP of thymic epithelial tumors in the setting of advanced disease. The identification of clinically relevant genomic alterations in the KIT, PI3K, CDKN2A/B, or NTRK genes provides a strong rationale for potential precision medicine approaches using targeted agents. A subset of thymic carcinomas show high tumor mutation burden, what may be a predictor of efficacy of immune checkpoint inhibitors., (© The Author(s) 2022. Published by Oxford University Press.)
- Published
- 2022
- Full Text
- View/download PDF
25. Management of cutaneous toxicities under amivantamab (anti MET and anti EGFR bispecific antibody) in patients with metastatic non-small cell lung cancer harboring EGFR Exon20ins: towards a proactive, multidisciplinary approach.
- Author
-
Basse C, Chabanol H, Bonte PE, Fromantin I, and Girard N
- Subjects
- Female, Humans, Male, ErbB Receptors genetics, Exanthema chemically induced, Exanthema prevention & control, Mutation, Paronychia chemically induced, Paronychia prevention & control, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms pathology, Protein Kinase Inhibitors toxicity, Skin Diseases chemically induced, Skin Diseases prevention & control
- Abstract
Contexte: The Epidermal Growth Factor Receptor (EGFR) is mutated in 10-15% of patients with lung adenocarcinoma. At metastatic stage EGFR tyrosine kinase inhibitors (TKIs) are used front line for patients harboring targetable mutations. Novel anti-EGFR therapies are being developed. Amivantamab is a bispecific anti-EGFR and anti-MET antibody with expected skin toxicities., Objective: We developed here guidelines for prevention and treatment of cutaneous toxicities under amivantamab according to our experience at Institut Curie., Materiel & Method: The first patients with metastatic lung cancer harboring EGFR Exon20ins mutation, included in the phase 1 CHRYSALIS trial and cured at Institute Curie from November 1st 2019 until December 31st 2021 were selected for this work. Retrospectively, all cutaneous adverse events were registered and classified according to the CTCAE 6.0 classification, and actions we implemented to minimize and treat these adverse events were collected. We then developed guidelines based on these datas., Results: A total of seven patients started amivantamab as monotherapy. The two most frequent dermatological adverse events were: acneiform rash and paronychia (100 % of patients). Other adverse events presented by the patients were reported: modification of hair growth with hypertrichosis in 50 % of men (n = 1/2) and hirsutism in 80 % of women (n = 4/5); skin abrasion of the scalp in 71 % (n = 5/7); and skin fissure in 57 % (n = 4/7). We recommend first a rigorous inspection of the skin and teguments to determine the risk rate to have dryer skin under treatment; second a prevention of paronychia/acneiform rash/and skin fissures with prophylactic tetracycline, skin moisturizing, and hygienic measures starting at least 14 days before treatment initiation; third a particular attention to the psychological impact of skin toxicities with access to psychological support., Conclusion: We propose here guidelines for the management of dermatological toxicities under amivantamab with a multidisciplinary approach for the proactive management of cutaneous toxicities with a focus on preventive actions., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2022 Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
26. EGFR -mutant NSCLC: monitoring the molecular evolution of tumors in 2022.
- Author
-
Girard N and Basse C
- Subjects
- Acrylamides, Angiogenesis Inhibitors therapeutic use, Aniline Compounds pharmacology, ErbB Receptors genetics, Evolution, Molecular, Humans, Immune Checkpoint Inhibitors, Indoles, Mutation, Protein Kinase Inhibitors, Pyrimidines, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Lung Neoplasms pathology
- Abstract
Introduction: Epidermal growth factor receptor ( EGFR) activating mutations define a subset of advanced, metastatic non-small cell lung cancers (NSCLCs), which was historically identified along with the clinical development of specific EGFR tyrosine kinase inhibitors (TKIs), opening the era of precision medicine in thoracic oncology., Areas Covered: Progression after EGFR TKIs is a major challenge for patients, as it occurs ineluctably along with disease evolution. Osimertinib is the current standard-of-care for the first-line treatment of EGFR -mutant NSCLC. Mechanisms of resistance to osimertinib are challenging to identify, and are dominated by MET pathway activation, and acquired EGFR mutations., Expert Opinion: The current vision for clinical practice in patients with EGFR -mutant NSCLC developing disease progression after osimertinib includes the following 5 steps:- continuation of osimertinib beyond progression, and local treatment of oligoprogressive disease, - comprehensive genomic profiling based on tissue rebiopsy of progressing sites, - access to new treatment agents through clinical trials, - molecular tumor board to discuss the off-label use of targeted agents, depending on the availability of drugs and/or expanded access programs - chemotherapy may be the best choice, based on combination of platinum-based regimen and antiangiogenic agents and possibly immune checkpoint inhibitors.
- Published
- 2022
- Full Text
- View/download PDF
27. [New drug approval: First-line lorlatinib in advanced ALK-positive non-small cell lung cancer].
- Author
-
Pasquier C and Basse C
- Subjects
- Aminopyridines therapeutic use, Drug Approval, Humans, Lactams, Lactams, Macrocyclic therapeutic use, Protein Kinase Inhibitors therapeutic use, Pyrazoles, Receptor Protein-Tyrosine Kinases, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy
- Published
- 2022
- Full Text
- View/download PDF
28. Brief Report on Teleconsultation in Lung Cancer: Toward a Semiotic Paradigm Shift?
- Author
-
Thomas QD, Basse C, Belaroussi Y, Beaucaire-Danel S, Daniel C, Quantin X, and Girard N
- Abstract
Introduction: Telehealth is taking an increasingly important part of medicine. This practice change is being accelerated by the pandemic linked to coronavirus disease 2019. Oncology is a medical specialty for which this paradigm shift is particularly relevant., Methods: We developed a survey aiming at evaluating the use of teleconsultation by physicians managing patients with lung cancer in France. The survey was available online from December 15, 2020, to February 10, 2021., Results: Answers were obtained from 142 clinicians (73.9% pneumologists, 18.3% medical oncologists, and 7.7% with another specialty), 129 (90.8%) of whom had already performed teleconsultation. Among those, 123 (95.3%) started after the coronavirus disease 2019 pandemic. In addition, 72.9% had a moderate usage of this tool (<10 teleconsultations/mo). The frequency of clinicians never using teleconsultation was higher in private practices ( p = 0.029). The two clinical situations for which teleconsultation was frequently used were visits during treatment without imaging assessment (53.5%) and post-treatment surveillance (80.3%). Depending on the type of treatment received, the frequency of teleconsultation was variable. Lung cancer subtype also affected the clinician's practice. Indeed, 47.2% never proposed this tool for SCLC. Teleconsultation was considered to be of no contribution, a moderate contribution, a significant contribution, or a revolution of the clinical practice for 14.1%, 66.2%, 10.6%, and 2.1% of the respondents, respectively. The participants expected to decrease, stabilize, or increase their teleconsultation activity in 18.3%, 52.8%, and 23.2% of the cases, respectively., Conclusions: Most thoracic oncologists in France are using teleconsultation, mostly as an additional tool that should not replace the doctor-patient in-person relationship., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
29. Pembrolizumab Plus Chemotherapy in Metastatic Thymic Carcinoma: A Case Report.
- Author
-
Thomas QD, Basse C, Luporsi M, and Girard N
- Abstract
Metastatic thymic carcinomas have a poor prognosis. Pembrolizumab, an anti-PD-1 antibody, has recently been evaluated for patients with metastatic thymic carcinomas progressing after at least one line of platinum-based chemotherapy. The antitumor activity of immunotherapy appears to be promising for these patients and pembrolizumab in monotherapy is actually a treatment option in second metastatic line. To the best of our knowledge, we report the first case of a patient treated for metastatic thymic adenocarcinoma with a combination of chemotherapy-immunotherapy. The patient is a 46-year-old man with metastatic thymic adenocarcinoma treated in third metastatic line with a combination of pembrolizumab plus platinum-based chemotherapy with a very good metabolic tumor response. He had a progression-free survival of 7.9 months and did not experience any severe side effects related to pembrolizumab. The association of immunotherapy and chemotherapy, as in non-small cell and small cell lung cancers, could be of interest for future therapeutic trials evaluating the survival of patients with metastatic thymic carcinoma., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Thomas, Basse, Luporsi and Girard.)
- Published
- 2022
- Full Text
- View/download PDF
30. Surgical or medical strategy for locally-advanced, stage IIIA/B-N2 non-small cell lung cancer: Reproducibility of decision-making at a multidisciplinary tumor board.
- Author
-
Mainguene J, Basse C, Girard P, Beaucaire-Danel S, Cao K, Brian E, Grigoroiu M, Gossot D, Luporsi M, Perrot L, Vieira T, Caliandro R, Daniel C, Seguin-Givelet A, and Girard N
- Subjects
- Humans, Neoplasm Staging, Pneumonectomy, Reproducibility of Results, Treatment Outcome, Carcinoma, Non-Small-Cell Lung pathology, Lung Neoplasms diagnosis, Lung Neoplasms pathology, Lung Neoplasms therapy
- Abstract
Background: Stage IIIA/B-N2 is a very heterogeneous group of patients and accounts for one third of NSCLC at diagnosis. The best treatment strategy is established at a Multidisciplinary Tumor Board (MTB): surgical resection with neoadjuvant or adjuvant therapy versus definitive chemoradiation with immune checkpoint inhibitors consolidation. Despite the crucial role of MTBs in this complex setting, limited data is available regarding its performances and the reproducibility of the decision-making., Methods: Using a large cohort of IIIA/B-N2 NSCLC patients, we described patient's characteristics and treatment strategies established at the initial MTB: with a "surgical strategy" group, for potentially resectable disease, and a "medical strategy" group for non-resectable patients. A third group consisted of patients who were not eligible for surgery after neoadjuvant treatment and switched from the surgical to the medical strategy. We randomly selected 30 cases (10 in each of the 3 groups) for a blinded re-discussion at a fictive MTB and analyzed the reproducibility and factors associated with treatment decision., Results: Ninety-seven IIIA/B-N2 NSCLC patients were enrolled between June 2017 and December 2019. The initial MTB opted for a medical or a surgical strategy in 44% and 56% of patients respectively. We identified histology, tumor size and localization, extent of lymph node involvement and the presence of bulky mediastinal nodes as key decision-making factors. Thirteen patients were not eligible for surgical resection after neoadjuvant therapy and switched for a medical strategy. Overall concordance between the initial decision and the re-discussion was 70%. The kappa correlation coefficient was 0.43. Concordance was higher for patients with limited mediastinal node invasion. Survival did not appear to be impacted by conflicting decisions., Conclusions: Reproducibility of treatment decision-making for stage IIIA/B-N2 NSCLC patients at a MTB is moderate but does not impact survival., (Copyright © 2021 Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
31. Thymic tumours and their special features.
- Author
-
Basse C and Girard N
- Subjects
- Diagnosis, Differential, Humans, Retrospective Studies, Myasthenia Gravis diagnosis, Myasthenia Gravis epidemiology, Myasthenia Gravis therapy, Thymoma diagnosis, Thymoma therapy, Thymus Neoplasms diagnosis, Thymus Neoplasms surgery
- Abstract
Thymic tumours are rare thoracic malignancies, that may be aggressive and difficult to treat. The pillars of the management include pathological review, consideration of differential diagnoses, staging and multidisciplinary discussion. Assessment of resectability is key to drive the treatment sequencing. Association with autoimmune diseases, especially myasthenia gravis, is observed, which impacts the oncological management. Networks are being built at the national and international levels. This article provides an overview of the most recent findings in the diagnosis, staging, histology, and management strategies of thymic tumours., Competing Interests: Conflict of interest: C. Girard has nothing to disclose. Conflict of interest: N. Basse has nothing to disclose., (Copyright ©The authors 2021.)
- Published
- 2021
- Full Text
- View/download PDF
32. Impact of COVID-19 on the management of patients with thoracic cancers in a tertiary referral center.
- Author
-
Basse C, Daniel C, Livartowski A, Beaucaire-Danel S, and Girard N
- Subjects
- Humans, Retrospective Studies, SARS-CoV-2, Tertiary Care Centers, COVID-19, Lung Neoplasms drug therapy, Lung Neoplasms epidemiology, Thoracic Neoplasms epidemiology, Thoracic Neoplasms therapy
- Abstract
Introduction: Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 has spread worldwide in 2020 leading the World Health Organization to declare a pandemic. Patients with thoracic cancers have been reported at higher risk to develop severe disease, and die from COVID-19. In this setting, clinical practice recommendations for the management of patients were published. We report here how these guidelines were implemented in a routine practice setting., Methods: We retrospectively collected the characteristics, treatment regimen and modification, as well as COVID-19 status and death for all patients with thoracic malignancies scheduled for an appointment at Institute Curie from March 23
rd to April 17th 2020., Results: A total of 339 patients were included. Treatment strategy was modified for a total of 110 (32 %) patients because of COVID-19; these modifications were in accordance with guidelines for 92 % of patients. The majority of dose modifications were related to immune checkpoint inhibitors, for which switch to flat dosing every 4-6 weeks was made. A total of 5 (1.5 %) patients were diagnosed with COVID-19 disease, 1 of whom died from disease complication., Conclusion: Our study provides a unique insight in the decision making for patients with thoracic malignancies in the setting of COVID-19 outbreak, showing how guidelines were implemented in the clinic, and what may be optimized in the clinical practice of thoracic oncology in the future., (Copyright © 2021. Published by Elsevier B.V.)- Published
- 2021
- Full Text
- View/download PDF
33. [NSCLC and new oncogenic mutations: Diagnosis and perspectives].
- Author
-
Basse C, Swalduz A, Mc Leer A, Moro-Sibilot D, Remon J, and Girard N
- Subjects
- Carcinogenesis, Humans, Molecular Targeted Therapy, Mutation, Protein-Tyrosine Kinases, Proto-Oncogene Proteins genetics, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung therapy, Lung Neoplasms diagnosis, Lung Neoplasms drug therapy, Lung Neoplasms genetics
- Abstract
The development of new targeted therapies in non-small cell lung carcinoma (NSCLC) depends on a better understanding of the molecular basis of carcinogenesis, a knowledge of the role of molecular aberrations in disease progression and the development of molecular biology platforms with the capacity to identify new biomarkers. In the current article, we review the techniques routinely used in cancer molecular biology platforms as well as new techniques under development. These new NSCLC biomarkers have been made available to clinicians and biologists in parallel with the development of targeted drugs. New molecular abnormalities of EGFR exon 20, HER2, MET, RET, BRAF, ROS1 and NTRK have been identified and there have been clinical trials of the most innovative targeted drugs., (Copyright © 2021 SPLF. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
34. Re: Clinical Characteristics and Outcomes of COVID-19-Infected Cancer Patients: A Systematic Review and Meta-Analysis.
- Author
-
Cottu P, Bozec L, Basse C, and Paoletti X
- Subjects
- Humans, SARS-CoV-2, COVID-19, Neoplasms drug therapy, Neoplasms epidemiology
- Published
- 2021
- Full Text
- View/download PDF
35. ["Fortuitous discovery of a thymoma"].
- Author
-
Basse C and Girard N
- Subjects
- Humans, Myasthenia Gravis, Thymoma diagnosis, Thymus Neoplasms diagnosis
- Abstract
Competing Interests: "Les auteurs déclarent n’avoir aucun lien d’intérêts."
- Published
- 2021
36. Characteristics and Outcome of SARS-CoV-2 Infection in Cancer Patients.
- Author
-
Basse C, Diakite S, Servois V, Frelaut M, Noret A, Bellesoeur A, Moreau P, Massiani MA, Bouyer AS, Vuagnat P, Malak S, Bidard FC, Vanjak D, Kriegel I, Burnod A, Bilger G, Ramtohul T, Dhonneur G, Bouleuc C, Cassoux N, Paoletti X, Bozec L, and Cottu P
- Subjects
- Aged, COVID-19 diagnosis, COVID-19 epidemiology, COVID-19 Testing methods, Comorbidity, Female, France epidemiology, Hospitalization statistics & numerical data, Humans, Intensive Care Units statistics & numerical data, Male, Middle Aged, Neoplasms diagnosis, Neoplasms epidemiology, Outcome Assessment, Health Care methods, Outcome Assessment, Health Care statistics & numerical data, Pandemics prevention & control, Risk Factors, SARS-CoV-2 genetics, SARS-CoV-2 physiology, Survival Analysis, Antiviral Agents therapeutic use, Neoplasms therapy, Registries statistics & numerical data, SARS-CoV-2 drug effects, COVID-19 Drug Treatment
- Abstract
Background: Concerns have emerged about the higher risk of fatal coronavirus disease 2019 (COVID-19) in cancer patients. In this article, we review the experience of a comprehensive cancer center., Methods: A prospective registry was set up at Institut Curie at the beginning of the COVID-19 pandemic. All cancer patients with suspected or proven COVID-19 were entered and actively followed for 28 days., Results: Among 9842 patients treated at Institut Curie between March 13 and May 1, 2020, 141 (1.4%) were diagnosed with COVID-19, based on reverse transcription polymerase chain reaction testing and/or computerized tomography scan. In line with our case mix, breast cancer (40.4%) was the most common tumor type, followed by hematological and lung malignancies. Patients with active cancer therapy or/and advanced cancer accounted for 87.9% and 68.9% of patients, respectively. At diagnosis, 78.7% of patients had COVID-19-related symptoms, with an extent of lung parenchyma involvement inferior to 50% in 95.8% of patients. Blood count variations and C-reactive protein elevation were the most common laboratory abnormalities. Antibiotics and antiviral agents were administered in 48.2% and 6.4% of patients, respectively. At the time of analysis, 26 patients (18.4%) have died from COVID-19, and 100 (70.9%) were cured. Independent prognostic factors at the time of COVID-19 diagnosis associated with death or intensive care unit admission were extent of COVID-19 pneumonia and decreased O
2 saturation., Conclusions: COVID-19 incidence and presentation in cancer patients appear to be very similar to those in the general population. The outcome of COVID-19 is primarily driven by the initial severity of infection rather than patient or cancer characteristics., (© The Author(s) 2021. Published by Oxford University Press.)- Published
- 2021
- Full Text
- View/download PDF
37. [New European approvals: Durvalumab - In first line metastatic small-cell lung cancer].
- Author
-
El Kaddissi A and Basse C
- Subjects
- Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carboplatin therapeutic use, Clinical Trials, Phase III as Topic, Humans, Immunotherapy, Nivolumab therapeutic use, Topotecan therapeutic use, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents therapeutic use, Drug Approval, Lung Neoplasms drug therapy, Small Cell Lung Carcinoma drug therapy
- Published
- 2020
- Full Text
- View/download PDF
38. [Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management].
- Author
-
Basse C, Swalduz A, Levra MG, Girard N, Remon J, and Moro-Sibilot D
- Subjects
- Anaplastic Lymphoma Kinase genetics, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung mortality, Clinical Trials, Phase III as Topic, Combined Modality Therapy methods, Disease Progression, Drug Resistance, Neoplasm physiology, Genes, erbB-1, Humans, Immunotherapy, Adoptive methods, Lung Neoplasms genetics, Lung Neoplasms mortality, Mutation, Receptors, Chimeric Antigen therapeutic use, Translocation, Genetic, Carcinoma, Non-Small-Cell Lung therapy, Immunotherapy methods, Lung Neoplasms therapy
- Abstract
Immunotherapy alone or in combination with chemotherapy is now an integral part of the treatment of metastatic NSCLC. This treatment is transforming the management of these cancers, with 20-30% of patients achieving long survival. However, disease progression under treatment is still the rule for the majority of patients, raising problems both in understanding its mechanisms and in subsequent appropriate management. This study examines current therapeutic options and proposes solutions to circumvent resistance to immunotherapy. The mechanisms of resistance to these treatments is also analysed., (Copyright © 2020 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
39. COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area.
- Author
-
Vuagnat P, Frelaut M, Ramtohul T, Basse C, Diakite S, Noret A, Bellesoeur A, Servois V, Hequet D, Laas E, Kirova Y, Cabel L, Pierga JY, Bozec L, Paoletti X, Cottu P, and Bidard FC
- Subjects
- Aged, Betacoronavirus, Breast Neoplasms epidemiology, Breast Neoplasms therapy, COVID-19, Cause of Death, Coronavirus Infections epidemiology, Coronavirus Infections therapy, Female, France epidemiology, Hospitalization, Humans, Lung diagnostic imaging, Lung pathology, Middle Aged, Pandemics, Pneumonia, Viral epidemiology, Pneumonia, Viral therapy, Prognosis, RNA, Viral blood, Risk Factors, SARS-CoV-2, Tomography, X-Ray Computed, Treatment Outcome, Breast Neoplasms complications, Breast Neoplasms pathology, Coronavirus Infections complications, Coronavirus Infections pathology, Pneumonia, Viral complications, Pneumonia, Viral pathology
- Abstract
Background: Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Institut Curie hospitals (ICH, Paris area, France)., Methods: An IRB-approved prospective registry was set up at ICH on March 13, 2020, for all breast cancer patients with COVID-19 symptoms or radiologic signs. Registered data included patient history, tumor characteristics and treatments, COVID-19 symptoms, radiological features, and outcome. Data extraction was done on April 25, 2020. COVID-19 patients were defined as those with either a positive RNA test or typical, newly appeared lung CT scan abnormalities., Results: Among 15,600 patients actively treated for early or metastatic breast cancer during the last 4 months at ICH, 76 patients with suspected COVID-19 infection were included in the registry and followed. Fifty-nine of these patients were diagnosed with COVID-19 based on viral RNA testing (N = 41) or typical radiologic signs: 37/59 (63%) COVID-19 patients were treated for metastatic breast cancer, and 13/59 (22%) of them were taking corticosteroids daily. Common clinical features mostly consisted of fever and/or cough, while ground-glass opacities were the most common radiologic sign at diagnosis. We found no association between prior radiation therapy fields or extent of radiation therapy sequelae and extent of COVID-19 lung lesions. Twenty-eight of these 59 patients (47%) were hospitalized, and 6 (10%) were transferred to an intensive care unit. At the time of analysis, 45/59 (76%) patients were recovering or had been cured, 10/59 (17%) were still followed, and 4/59 (7%) had died from COVID-19. All 4 patients who died had significant non-cancer comorbidities. In univariate analysis, hypertension and age (> 70) were the two factors associated with a higher risk of intensive care unit admission and/or death., Conclusions: This prospective registry analysis suggests that the COVID-19 mortality rate in breast cancer patients depends more on comorbidities than prior radiation therapy or current anti-cancer treatment. Special attention must be paid to comorbidities when estimating the risk of severe COVID-19 in breast cancer patients.
- Published
- 2020
- Full Text
- View/download PDF
40. Sarcomas in patients over 90: Natural history and treatment-A nationwide study over 6 years.
- Author
-
Basse C, Italiano A, Penel N, Mir O, Chemin C, Toulmonde M, Duffaud F, Le Cesne A, Chevreau C, Maynou C, Anract P, Gouin F, Rios M, Firmin N, Kurtz JE, Kerbrat P, Piperno-Neumann S, Bertucci F, Rosset P, Isambert N, Bompas E, Dubray-Longeras P, Fiorenza F, Le Maignan C, Chaigneau L, Thyss A, Bouché O, Eymard JC, Delcambre Lair C, Adam J, Karanian M, Lebbé C, Dupré A, Meeus P, Brahmi M, Dufresne A, Ducimetière F, Ray-Coquard I, and Blay JY
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Child, Child, Preschool, Disease-Free Survival, Female, France epidemiology, Humans, Infant, Infant, Newborn, Male, Middle Aged, Neoplasm Recurrence, Local, Sarcoma diagnosis, Sarcoma epidemiology, Soft Tissue Neoplasms diagnosis, Soft Tissue Neoplasms epidemiology, Young Adult, Databases, Factual statistics & numerical data, Registries statistics & numerical data, Sarcoma therapy, Soft Tissue Neoplasms therapy
- Abstract
Soft tissue sarcomas (STS) are rare tumors accounting for less than 1% of human cancers. While the highest incidence of sarcomas is observed in elderly, this population is often excluded or poorly represented in clinical trials. The present study reports on clinicopathological presentation, and outcome of sarcoma patients over 90 recorded in the Netsarc.org French national database. NETSARC (netsarc.org) is a network of 26 reference sarcoma centers with specialized multidisciplinary tumor board (MDTB), funded by the French National Cancer Institute to improve the outcome of sarcoma patients. Since 2010, presentation to an MDTB, second pathological review, and collection of sarcoma patient characteristics and follow-up are collected in a database Information of patients registered from January 1, 2010, to December 31, 2016, in NETSARC were collected, analyzed and compared to the younger population. Patients with sarcomas aged >90 have almost exclusively sarcomas with complex genomics (92.0% vs. 66.3%), are less frequently metastatic (5.3% vs. 14·7%) at diagnosis, have more often superficial tumors (39.8% vs. 14.7%), as well as limbs and head and neck sites (75.2% vs. 38.7%) (all p < 0.001). Optimal diagnostic procedures and surgery were less frequently performed in patients over 90 (p < 0.001). These patients were less frequently operated in NETSARC centers, as compared to those of younger age groups including aged 80-90. However, local relapse-free survival, metastatic relapse-free survival and relapse-free survival were not significantly different from those of younger patients, in the whole cohort, as well as in the subgroup of operated patients. As expected overall survival was worse in patients over 90 (p < 0.001). Patients over 90 who were not operated had worse overall survival than younger patients (9.9 vs. 27.3 months, p < 0.001). Patients with STS diagnosed after 90 have distinct clinicopathological features, but comparable relapse-free survival, unless clinical practice guidelines recommendations are not applied. Standard management should be proposed to these patients if oncogeriatric status allows., (© 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)
- Published
- 2019
- Full Text
- View/download PDF
41. Exploitation of Precision Medicine Trials Data: Examples of Long Responders From the SHIVA01 Trial.
- Author
-
Basse C, Morel C, Callens C, Pierron G, Servois V, Vincent-Salomon A, Jobard A, Alt M, Ricci F, Loirat D, Sablin MP, Bretagne M, Saint-Ghislain M, Hescot S, Gonçalves A, Tredan O, Dubot C, Gavoille C, Delord JP, Campone M, Isambert N, Belin L, Bieche I, Kamal M, and Le Tourneau C
- Abstract
Purpose: Precision medicine trials constitute a precious source of molecular data with prospective clinical annotations allowing the exploration of patients' subpopulations according to specific clinical or biological questions. Using the SHIVA01-the first randomized trial comparing molecularly targeted therapy on the basis of tumor molecular profiling versus conventional chemotherapy in metastatic cancer patients who failed standard of care therapy-annotated database, we report cases of patients treated in the trial with targeted therapy who experienced an objective response or prolonged disease stabilization in light of patients' molecular alterations., Patients and Methods: We selected all patients included in SHIVA01 treated with a molecularly targeted agent (MTA) who experienced an objective response or disease stabilization that lasted longer than 6 months according to Response Evaluation Criteria in Solid Tumors version 1.1., Results: Among the 170 patients who received MTAs in the SHIVA01 trial, 15 patients (9%) experienced an objective response (n = 3) or disease stabilization that lasted longer than 6 months (n = 12). The most frequent histologic subtypes were breast cancer (27%) and cervical cancer (20%). Six patients, including three patients with breast cancer, were treated with abiraterone on the basis of androgen receptor protein overexpression. Five patients were treated with everolimus on the basis of a PTEN heterozygous deletion with loss of protein expression, PIK3CA mutation, or both alterations. The remaining four patients were treated with tamoxifen, erlotinib, imatinib, and vemurafenib on the basis of progesterone receptor expression, EGFR amplification, KIT mutation, and BRAF mutation, respectively. TP53 mutations were absent in responder patients., Conclusion: Analysis of patients who experienced objective responses or disease stabilization that lasted longer than 6 months allowed the identification of potential biomarkers of sensitivity and resistance to MTAs., Competing Interests: Clinical trials information: NCT01771458.The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Clémence BasseNo relationship to discloseClaire MorelNo relationship to discloseCéline CallensNo relationship to discloseGaëlle PierronNo relationship to discloseVincent ServoisNo relationship to discloseAnne Vincent-SalomonHonoraria: Roche, AstraZeneca Research Funding: NanoString Technologies (Inst) Travel, Accommodations, Expenses: NanoString Technologies, GenentechAude JobardTravel, Accommodations, Expenses: BayerMarie AltNo relationship to discloseFrancesco RicciNo relationship to discloseDelphine LoiratConsulting or Advisory Role: Roche, MSD Oncology, Bristol-Myers SquibbMarie-Paule SablinNo relationship to discloseMarie BretagneNo relationship to discloseMathilde Saint-GhislainNo relationship to discloseSégolène HescotNo relationship to discloseAnthony GonçalvesResearch Funding: MSD Oncology (Inst), Bristol-Myers Squibb (Inst), Novartis (Inst), Cascadian Therapeutics (Inst), Nektar (Inst), Boehringer Ingelheim (Inst), Eli Lilly (Inst), AbbVie (Inst) Travel, Accommodations, Expenses: Pfizer, Novartis, Genentech, CelgeneOlivier TredanConsulting or Advisory Role: Roche, Pfizer, Novartis, Eli Lilly, AstraZeneca, MSD Oncology, Roche Research Funding: Novartis, Pfizer, Eli Lilly, Bristol-Myers Squibb, MSD Oncology, AstraZeneca Travel, Accommodations, Expenses: Roche, Novartis, Pfizer, Eli Lilly, AstraZenecaCoraline DubotNo relationship to discloseCéline GavoilleNo relationship to discloseJean-Pierre DelordNo relationship to discloseMario CamponeHonoraria: Novartis, Servier, Menarini Consulting or Advisory Role: Novartis (Inst), Servier (Inst), Menarini, Sanofi (Inst), Eli Lilly (Inst), Pfizer (Inst), AstraZeneca (Inst), MedImmune (Inst) Speakers' Bureau: Novartis, Amgen Research Funding: Novartis (Inst) Travel, Accommodations, Expenses: Novartis Other Relationship: RocheNicolas IsambertTravel, Accommodations, Expenses: Celgene, PharmaMar, Novartis, AstraZeneca, MedImmune, GenentechLisa BelinNo relationship to discloseIvan BiecheNo relationship to discloseMaud KamalNo relationship to discloseChristophe Le TourneauHonoraria: Novartis, Bristol-Myers Squibb Consulting or Advisory Role: Amgen, MSD Oncology, Bristol-Myers Squibb, Merck Serono, AstraZeneca Travel, Accommodations, Expenses: MSD Oncology, Bristol-Myers Squibb, AstraZeneca, (© 2018 by American Society of Clinical Oncology.)
- Published
- 2018
- Full Text
- View/download PDF
42. Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie.
- Author
-
Basse C, Morel C, Alt M, Sablin MP, Franck C, Pierron G, Callens C, Melaabi S, Masliah-Planchon J, Bataillon G, Gardrat S, Lavigne M, Bonsang B, Vaflard P, Pons Tostivint E, Dubot C, Loirat D, Marous M, Geiss R, Clément N, Schleiermacher G, Kamoun C, Girard E, Ardin M, Benoist C, Bernard V, Mariani O, Rouzier R, Tresca P, Servois V, Vincent-Salomon A, Bieche I, Le Tourneau C, and Kamal M
- Abstract
Background: High throughput molecular screening techniques allow the identification of multiple molecular alterations, some of which are actionable and can be targeted by molecularly targeted agents (MTA). We aimed at evaluating the relevance of using this approach in the frame of Institut Curie Molecular Tumor Board (MTB) to guide patients with cancer to clinical trials with MTAs., Patients and Methods: We included all patients presented at Institut Curie MTB from 4 October 2014 to 31 October 2017. The following information was extracted from the chart: decision to perform tumour profiling, types of molecular analyses, samples used, molecular alterations identified and those which are actionable, and inclusion in a clinical trial with matched MTA., Results: 736 patients were presented at the MTB. Molecular analyses were performed in 442 patients (60%). Techniques used included next-generation sequencing, comparative genomic hybridisation array and/or other techniques including immunohistochemistry in 78%, 51% and 58% of patients, respectively. Analyses were performed on a fresh frozen biopsy in 91 patients (21%), on archival tissue (fixed or frozen) in 326 patients (74%) and on both archival and fresh frozen biopsy in 25 patients (6%). At least one molecular alteration was identified in 280 analysed patients (63%). An actionable molecular alteration was identified in 207 analysed patients (47%). Forty-five analysed patients (10%) were enrolled in a clinical trial with matched MTA and 29 additional patients were oriented and included in a clinical trial based on a molecular alteration identified prior to the MTB analysis. Median time between date of specimen reception and molecular results was 28 days (range: 5-168)., Conclusions: The implementation of an MTB at Institut Curie enabled the inclusion of 10% of patients into a clinical trial with matched therapy., Competing Interests: Competing interests: None declared.
- Published
- 2018
- Full Text
- View/download PDF
43. Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort.
- Author
-
Basse C, Thureau S, Bota S, Dansin E, Thomas PA, Pichon E, Lena H, Massabeau C, Clément-Duchene C, Massard G, Westeel V, Quantin X, Oulkhouir Y, Danhier S, Lerouge D, Tanguy R, Thillays F, Le Pechoux C, Dubray B, Thiberville L, Besse B, and Girard N
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Cohort Studies, Female, Humans, Middle Aged, Neoplasms, Glandular and Epithelial pathology, Postoperative Care, Prospective Studies, Thymus Neoplasms pathology, Young Adult, Neoplasms, Glandular and Epithelial radiotherapy, Thymus Neoplasms radiotherapy
- Abstract
Introduction: Thymic epithelial tumors (TETs) are rare intrathoracic malignancies for which surgery represents the mainstay of the treatment. Current practice for postoperative radiotherapy (PORT) is highly variable, and there is a lack of prospective, high level evidence. Réseau Tumeurs Thymiques et Cancer (RYTHMIC) is the nationwide network for TETs in France. Established in 2012, it prospectively collects data on all TET patients, for whom management is discussed at a national multidisciplinary tumor board (MTB). We assessed whether PORT decisions at the MTB were in accordance with RYTHMIC guidelines and ultimately implemented in patients., Methods: All consecutive patients for whom PORT was discussed at the MTB from 2012 to 2015 were identified from the RYTHMIC prospective database, and a complete review of their medical records was performed., Results: A total of 274 patients, including 243 with thymoma (89%) and 31 with thymic carcinoma (11%), were analyzed. The decision of the MTB was in accordance with guidelines in 221 patients (92%) of the 241 with stage I or III TET. An MTB decision to deliver PORT was made for 117 patients (43%). PORT was ultimately initiated in 101 patients. The most frequent reason for not delivering PORT was excessive (>3 months) delay after surgery. Dose-volume constraints defined by the International Thymic Malignancy Interest Group were followed in all but four patients., Conclusion: Our data provide a unique insight into the decision-making process for PORT in TETs, highlighting the need for systematic discussion at an expert MTB, while stressing the value of current available guidelines., (Copyright © 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
44. [Cell cycle inhibitors in endocrine receptor positive breast cancer].
- Author
-
Sablin MP, Ricci F, Loirat D, Jobard A, Basse C, Romano E, Le Tourneau C, and Dieras V
- Subjects
- Aminopyridines adverse effects, Aminopyridines therapeutic use, Antineoplastic Agents adverse effects, Benzimidazoles adverse effects, Benzimidazoles therapeutic use, Breast Neoplasms chemistry, Breast Neoplasms pathology, Cell Cycle physiology, Cell Cycle Checkpoints, Clinical Trials as Topic, Cyclin-Dependent Kinase 4 physiology, Cyclin-Dependent Kinase 6 physiology, Female, Humans, Neoplasms, Hormone-Dependent chemistry, Piperazines adverse effects, Piperazines therapeutic use, Protein Kinase Inhibitors adverse effects, Purines adverse effects, Purines therapeutic use, Pyridines adverse effects, Pyridines therapeutic use, Antineoplastic Agents therapeutic use, Breast Neoplasms drug therapy, Cyclin-Dependent Kinase 4 antagonists & inhibitors, Cyclin-Dependent Kinase 6 antagonists & inhibitors, Neoplasms, Hormone-Dependent drug therapy, Protein Kinase Inhibitors therapeutic use
- Abstract
Dysregulation of cellular cycle is a key component of carcinogenesis and its targeting represents an interesting approach. Recently, the development of selective inhibitors of the cycle targeting the cyclin-dependent kinases (CDK) 4 and 6 revived interest in this therapeutic class after the failure of pan-inhibitors. Palbociclib, ribociclib, and abemaciclib are the 3 drugs with the most advanced development. They demonstrated preclinical activity in luminal breast cancer models and are under clinical evaluation. The first available studies demonstrate the value of these compounds with an improved prognosis of metastatic patients in combination with endocrine therapy (palbociclib, ribociclib) or in monotherapy (abemaciclib). The results of ongoing studies will clarify the role of these agents in our new strategies and the individualisation of biomarkers will help to define patients who benefit most from this approach., (Copyright © 2016 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
45. Postoperative Radiotherapy in Completely Resected Stage II and III Thymoma: How to Translate the Potential Survival Benefit in the Setting of the Future Adoption of the IASLC-ITMIG TNM-Based Staging System.
- Author
-
Basse C, Merveilleux du Vignaux C, and Girard N
- Subjects
- Forecasting, Humans, Neoplasm Staging, Radiotherapy, Adjuvant, Thymus Neoplasms, Lung Neoplasms, Thymoma
- Published
- 2017
- Full Text
- View/download PDF
46. The increasing roles of epigenetics in breast cancer: Implications for pathogenicity, biomarkers, prevention and treatment.
- Author
-
Basse C and Arock M
- Subjects
- Biomarkers, Tumor genetics, Biomarkers, Tumor metabolism, Breast Neoplasms metabolism, Breast Neoplasms pathology, Breast Neoplasms therapy, DNA Methylation, Female, Humans, MicroRNAs genetics, Tumor Microenvironment, Breast Neoplasms genetics, Epigenesis, Genetic, Gene Expression Regulation, Neoplastic
- Abstract
Nowadays, the mechanisms governing the occurrence of cancer are thought to be the consequence not only of genetic defects but also of epigenetic modifications. Therefore, epigenetic has become a very attractive and increasingly investigated field of research in order to find new ways of prevention and treatment of neoplasia, and this is particularly the case for breast cancer (BC). Thus, this review will first develop the main known epigenetic modifications that can occur in cancer and then expose the future role that control of epigenetic modifications might play in prevention, prognostication, follow-up and treatment of BC. Indeed, epigenetic biomarkers found in peripheral blood might become new tools to detect BC, to define its prognostic and to predict its outcome, whereas epi-drugs might have an increasing potential of development in the next future. However, if DNA methyltransferase inhibitors and histone desacetylase inhibitors have shown encouraging results in BC, their action remains nonspecific. Thus, additional clinical studies are needed to evaluate more precisely the effects of these molecules, even if they have provided encouraging results in cotreatment and combined therapies. This review will also deal with the potential of RNA interference (RNAi) as epi-drugs. Finally, we will focus on the potential prevention of BC through epigenetic based on diet and we will particularly develop the possible place of isothiocyanates from cruciferous vegetables or of Genistein from soybean in a dietary program that might potentially reduce the risk of BC in large populations., (© 2014 UICC.)
- Published
- 2015
- Full Text
- View/download PDF
47. Dogs showing separation-related behaviour exhibit a 'pessimistic' cognitive bias.
- Author
-
Mendl M, Brooks J, Basse C, Burman O, Paul E, Blackwell E, and Casey R
- Subjects
- Animals, Dogs, Humans, Male, Neuropsychological Tests, Affect, Behavior, Animal
- Published
- 2010
- Full Text
- View/download PDF
48. Fungal gene expression during pathogenesis-related development and host plant colonization.
- Author
-
Kahmann R and Basse C
- Subjects
- Fungi genetics, Fungi growth & development, Virulence genetics, Fungal Proteins genetics, Fungal Proteins metabolism, Fungi pathogenicity, Gene Expression Regulation, Fungal, Plant Diseases microbiology
- Abstract
To successfully infect plants, pathogenic fungi must recognize and communicate with their host during different stages of the disease cycle. In past years, techniques such as insertional mutagenesis, sensitive GFP-based reporter systems and microarray techniques have been developed to analyze these processes at the molecular level, and now novel insights into this fascinating aspect of pathogen-plant communication are beginning to emerge. This is exemplified by a number of pathogenicity genes functioning in distinct stages of pathogenic development in Magnaporthe grisea.
- Published
- 2001
- Full Text
- View/download PDF
49. Characterization of a Ustilago maydis gene specifically induced during the biotrophic phase: evidence for negative as well as positive regulation.
- Author
-
Basse CW, Stumpferl S, and Kahmann R
- Subjects
- Amino Acid Sequence, Base Sequence, Molecular Sequence Data, Saccharomyces cerevisiae Proteins, Zinc Fingers genetics, DNA-Binding Proteins genetics, Gene Expression Regulation, Fungal, Genes, Fungal, Repressor Proteins genetics, Ustilago genetics
- Abstract
The phytopathogenic basidiomycete Ustilago maydis requires its host plant, maize, for completion of its sexual cycle. To investigate the molecular events during infection, we used differential display to identify plant-induced U. maydis genes. We describe the U. maydis gene mig1 (for "maize-induced gene"), which is not expressed during yeast-like growth of the fungus, is weakly expressed during filamentous growth in axenic culture, but is extensively upregulated during plant infection. mig1 encodes a small, highly charged protein of unknown function which contains a functional N-terminal secretion sequence and is not essential for pathogenic development. Adjacent to mig1 is a second gene (mdu1) related to mig1, which appears to result from a gene duplication. mig1 gene expression during the infection cycle was assessed by fusing the promoter to eGFP. Expression of mig1 was absent in hyphae growing on the leaf surface but was detected after penetration and remained high during subsequent proliferation of the fungus until teliospore formation. Successive deletions as well as certain internal deletions in the mig1 promoter conferred elevated levels of reporter gene expression during growth in axenic culture, indicative of negative regulation. During fungal growth in planta, sequence elements between positions -148 and -519 in the mig1 promoter were specifically required for high levels of induction, illustrating additional positive control. We discuss the potential applications of mig1 for the identification of inducing compounds and the respective regulatory genes.
- Published
- 2000
- Full Text
- View/download PDF
50. Fungal-plant signalling in the Ustilago maydis-maize pathosystem.
- Author
-
Kahmann R, Basse C, and Feldbrügge M
- Subjects
- Cyclic AMP metabolism, Gene Expression Regulation, Fungal, MAP Kinase Signaling System, Signal Transduction, Ustilago genetics, Ustilago growth & development, Zea mays microbiology
- Abstract
The smut fungus Ustilago maydis needs the host plant maize for completion of its sexual life cycle. Recent experiments highlight the importance of cAMP and mitogen-activated protein (MAP) kinase signalling for cell fusion as well as for subsequent stages of plant colonisation and induction of disease symptoms. During these distinct developmental stages the same signalling cascades must be differentially regulated and accommodate multiple inputs and outputs.
- Published
- 1999
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.